Design Therapeutics is a company.
Design Therapeutics has raised $176.0M across 2 funding rounds.
Key people at Design Therapeutics.
Design Therapeutics has raised $176.0M in total across 2 funding rounds.
Key people at Design Therapeutics.
Design Therapeutics has raised $176.0M in total across 2 funding rounds.
Design Therapeutics's investors include Morgenthaler Ventures, OrbiMed, Samsara BioCapital, SR One.
Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics, specifically GeneTAC™ (Gene Targeted Chimera) molecules, aimed at treating serious genetic degenerative diseases by modulating gene expression without gene editing. Their proprietary platform designs precision medicines that can dial gene expression up or down, targeting the root causes of inherited conditions such as Friedreich ataxia, Huntington’s disease, and myotonic dystrophy. The company serves patients suffering from debilitating genetic disorders, addressing significant unmet medical needs with a pipeline advancing through preclinical and clinical stages, demonstrating promising growth momentum in the biopharmaceutical sector[1][2][5].
Founded in 2017, Design Therapeutics was established with a vision to restore health by harnessing the body’s own biology through DNA-targeted small molecules. The leadership, including CEO Dr. João Siffert, brings deep expertise in medicinal chemistry, transcription modulation, and clinical development. The idea emerged from the challenge of treating genetic diseases with complex modalities like gene therapy, leading to the innovative GeneTAC™ platform that offers a potentially safer, more versatile small molecule approach. Early clinical results, such as those from their lead candidate DT-216 for Friedreich ataxia, have validated the platform’s mechanism, marking pivotal moments in their trajectory[2][4][5][7].
Design Therapeutics rides the growing trend of precision genomic medicine, particularly the shift towards small molecule approaches for genetic diseases, which are often safer and more easily administered than gene editing or gene therapy. The timing is critical as advances in medicinal chemistry and genomic understanding converge, enabling targeted treatments for previously intractable genetic disorders. Market forces such as increasing demand for therapies addressing rare and degenerative diseases, alongside regulatory encouragement for innovative treatments, work in their favor. By pioneering small molecule genomic medicines, Design Therapeutics influences the biotech ecosystem by expanding therapeutic options and potentially lowering barriers to treatment access[1][2][5].
Looking ahead, Design Therapeutics is poised to advance its clinical pipeline, particularly progressing candidates like DT-216 through later-stage trials while expanding its platform applications to other genetic diseases. Trends shaping their journey include the maturation of genomic medicine, growing patient advocacy for rare disease treatments, and potential partnerships to accelerate commercialization. Their influence may evolve from a niche innovator to a broader leader in small molecule gene modulation therapies, potentially transforming treatment paradigms for genetic disorders and impacting the biotech industry’s approach to precision medicine[1][2][3][5].
Design Therapeutics has raised $176.0M across 2 funding rounds. Most recently, it raised $130.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $130.0M Series B | Morgenthaler Ventures, OrbiMed, Samsara BioCapital, SR One | |
| Mar 1, 2020 | $46.0M Series A | Morgenthaler Ventures, OrbiMed, Samsara BioCapital, SR One |
